Randomized Controlled Trial of Macrolide Therapy for Mycoplasma pneumoniae

项目总结 社区获得性肺炎(CAP)是第五大流行但代价第二高的原因 儿童住院治疗。肺炎支原体(MP)是最常见的病原体 细菌冠状病毒。虽然大环内酯类药物被推荐用于MP CAP的治疗，但缺乏明确的 支持大环内酯类药物治疗MP的证据可能导致了大环内酯类药物的过度使用。这辆R34 应用“大环内酯类药物治疗MP的随机对照试验”将有助于开发完整的 未来审判的礼仪和相关文件。在未来的试验中，我们将随机选择那些 因MP CAP住院接受β-内酰胺和阿奇霉素或β-内酰胺和安慰剂。这场审判将 为MP CAP住院儿童的靶向治疗提供必要的证据，导致使用 预防过度治疗减少并发症的同时进行必要治疗 流行的疾病。

PROJECT SUMMARY Community-acquired pneumonia (CAP) is the fifth most prevalent but second most costly reason for hospitalization in children. Mycoplasma pneumoniae (Mp) is the most frequently detected pathogen cause bacterial CAP. Although macrolides are recommended for the treatment of Mp CAP there is a lack of clear evidence to support macrolide treatment for Mp has which has likely led to the overuse of macrolides. This R34 application, “Randomized Controlled Trial of Macrolide Therapy for Mp”, will aide in the development of the full protocol and relevant documents for the future trial. In the future trial, we will randomize children who are hospitalized with Mp CAP to receive beta-lactam and azithromycin or beta-lactam and placebo. This trial will provide the necessary evidence for targeted therapy in children hospitalized with Mp CAP, leading to the use of necessary therapy while preventing over-treatment and decreasing complications for children with this prevalent disease.